NSW2050 - Camperdown - Chris O'Brien Lifehouse (WITHDRAWN)2065 - St Leonards - GenesisCare North Shore Private Hospital (WITHDRAWN)2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (WITHDRAWN)

NZNZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (WITHDRAWN)

NCT05142189

LuCa-MERIT-1: First-in-human, Open Label, Phase I Dose Confirmation Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

NCT05123482

A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR) (D6900C00001)

QLD4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (WITHDRAWN)

NCT05117476

A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

VIC3004 - Melbourne, Southbank - Alfred Health (COMPLETED)3168 - Clayton - Monash Medical Centre (COMPLETED)

WA6009 - Nedlands - Linear Clinical Research (COMPLETED)

NCT05094336

A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors (MTAPESTRY-101)

NCT05086692

A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (ABILITY-1)

NCT05081609

IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (IL-Believe)

5065 - Toorak Gardens - Burnside War Memorial Hospital (TERMINATED)

NCT05067283

A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors (KANDLELIT-001)

NZNZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (COMPLETED)

NCT04995523

Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01)

VIC3000 - Melbourne - Peter MacCallum Cancer Centre (COMPLETED)

NCT04956640

A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors (LOXO-RAS-20001)

NCT04928846

A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (M18-868)

NCT04895709

A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (CA052-002)

NCT04830202

Expanded Access to Telisotuzumab Vedotin (C20-503)

NCT04686305

A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03) (DL03)

VIC3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (WITHDRAWN)

NCT04665206

Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors (VT3989-001)

NCT04614103

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer (IOV-LUN-202)

NCT04613596

A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (CA239-0009)

3168 - Clayton - Monash Medical Centre (WITHDRAWN)

NCT04606446

A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS (KAT6)

NSW2050 - Camperdown - Chris O'Brien Lifehouse (TERMINATED)

NCT04585750

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

NCT04449874

A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (GO42144)

NA

NCT03175224

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

NCT03093116

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

NSW2050 - Camperdown - Chris O'Brien Lifehouse (COMPLETED)

VIC3000 - Melbourne - Peter MacCallum Cancer Centre (COMPLETED)3002 - East Melbourne - Epworth Freemasons (COMPLETED)

SA5042 - Bedford Park - Flinders Medical Centre (COMPLETED)

NCT02468024

JoLT-Ca A Randomized Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC), The STABLE-MATES Trial

ACTRN12625000203459

An open-label, multicenter, Phase I/IIa study assessing the safety and efficacy of EGFR targeted EDVsTM carrying cytotoxic drug PNU-159682 plus concurrent immunomodulatory adjuvant non-targeted EDVs carrying a-galactosyl ceramide in subjects with advanced EGFR-expressing cancers who have failed second-line therapy or where first- and/or second-line therapy is not appropriate (EGFR EDV-D682/GC Trial) (ENG19)

ACTRN12623000652673

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ELVN-002 in Healthy Adult Volunteers: Part C Open-label Drug-Drug Interaction (ELVN-002-002)

ACTRN12623000552684

OCEANiC: A Phase II, Open-label, Multi-centre Clinical Trial on effect of Osimertinib, With or Without Adjuvant Chemotherapy, Guided by High-risk Tumour Next Generation Sequencing (NGS) Co-mutation Status and circulating tumour DNA (ctDNA) Detection on disease-free survival in Patients With Stage IIA-IIIA epidermal growth factor receptor (EGFR)-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection

ACTRN12621000951853

Not Applicable

Pilot Study of Fesability of Neoadjuvant Radiosurgery for Breast Cancer and Non-Small Cell Lung Cancer Intracranial Metastases (NEST-Trial)

ACTRN12621000848808

A Single Dose Phase 1 Study in Healthy Participants to Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Caucasian and Ethnic Chinese Populations (EQ143-101)

NCT03906331

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

PD-1/PD-L1	50%
PD-1	45%
EGFR	20%
KRAS	13%
KRAS G12C	11%
PD-L1	10%
Trop2	9%
TIGIT	8%
ERBB2	8%
MET	6%
PRMT5	5%
VEGF	4%
ALK	3%
ER	3%
oestrogen axis	3%
LAG3	3%
CTLA4	3%
ROS1	3%
CDK4	3%
RET	3%
FR-alpha	3%
BRAF	3%
RAF	3%
ERBB3	2%
VEGFA	2%
KAT6	2%
CDK6	2%
PI3K alpha	2%
Nectin4	2%
MEK	2%
CDK4 selective	2%
PARP	2%
PARP1-selective	2%
IL-2	2%
TRK	2%
VEGFR2	1%
prostaglandin DP1 receptor	1%
prostaglandin EP2 receptor	1%
prostaglandin EP4 receptor	1%
CEACAM5	1%
EGFR CDAC	1%
KRAS G12D	1%
SMARCA2	1%
GPC3	1%
DPD	1%
orotate phosphoribosyltransferase	1%
HRAS G12C	1%
NRAS G12C	1%
CRAF	1%
pan-RAF	1%
B7H3	1%
GARP	1%
MAT2A	1%
CD73	1%
BRAF V600	1%
B7H4	1%
MICA/MICB	1%
TLR7/TLR8	1%
CCR8	1%
YAP-TEAD	1%
TP53	1%
TP53 Y220C	1%
SHP2	1%
SMO	1%

ARTICANZ - Beta (ver 0.91)

Search results

Respiratory / Non small cell lung cancer

Filters